Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Dulaglutide 1.5 mg subcutaneous once weekly Dulaglutide 1.5 mg plus calorie restricted diet	calorie restricted diet 1000 to 1300 kcal with dietitian follow up and exercise advice; lifestyle: intensive	35	35
A2	Standard care or no added treatment Calorie restricted diet alone	calorie restricted diet 1000 to 1300 kcal with dietitian follow up and exercise advice; lifestyle: intensive	33	33

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Dulaglutide 1.5 mg subcutaneous once weekly A1	Standard care or no added treatment A2
age	mean (years)	30.31	28.64
bmi	mean (kg/m2)	29.68	29.71
hba1c	mean (percent)	5.72	5.64
sbp	mean (mmHg)	124.14	127.69
waist	mean (cm)	96.76	94.89
weight	mean (kg)	77.62	78.84

Analyses this trial contributes to

Discontinuation due to adverse events
Polycystic ovary syndrome; longest follow-up; descriptive only
Discontinuation due to adverse events
Polycystic ovary syndrome; longest follow-up; descriptive only
Nausea
Polycystic ovary syndrome; longest follow-up; network meta-analysis
Nausea
Polycystic ovary syndrome; longest follow-up; network meta-analysis
Vomiting
Polycystic ovary syndrome; longest follow-up; descriptive only
Vomiting
Polycystic ovary syndrome; longest follow-up; descriptive only
Diarrhea
Polycystic ovary syndrome; longest follow-up; network meta-analysis
Diarrhea
Polycystic ovary syndrome; longest follow-up; network meta-analysis
Constipation
Polycystic ovary syndrome; longest follow-up; descriptive only
Constipation
Polycystic ovary syndrome; longest follow-up; descriptive only
Discontinuation due to gastrointestinal adverse events
Polycystic ovary syndrome; longest follow-up; descriptive only
Discontinuation due to gastrointestinal adverse events
Polycystic ovary syndrome; longest follow-up; descriptive only

Results

12 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

Discontinuation due to adverse events (2 lines; O26)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				2 / 35	not stated; randomized; R0009547:Table 3
	A2	events				0 / 33	not stated; randomized; R0009547:Table 3

Nausea (2 lines; O27A)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				8 / 35	not stated; randomized; R0009547:Table 3
	A2	events				0 / 33	not stated; randomized; R0009547:Table 3

Vomiting (2 lines; O27B)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				7 / 35	not stated; randomized; R0009547:Table 3
	A2	events				0 / 33	not stated; randomized; R0009547:Table 3

Diarrhea (2 lines; O27C)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				0 / 35	not stated; randomized; R0009547:Table 3
	A2	events				0 / 33	not stated; randomized; R0009547:Table 3

Constipation (2 lines; O27D)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				4 / 35	not stated; randomized; R0009547:Table 3
	A2	events				0 / 33	not stated; randomized; R0009547:Table 3

Discontinuation due to gastrointestinal adverse events (2 lines; O27E)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
	A1	events				2 / 35	not stated; randomized; R0009547:Results
	A2	events				0 / 33	not stated; randomized; R0009547:Table 3

NCT04876027

Design

Conduct and analysis

Arms

Baseline characteristics

Analyses this trial contributes to

Results